Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Racquel Innis-Shelton M.D.
Associate Professor
Close
E-mail
rishelton@uabmc.edu
ishelton@uab.edu
Phone
205-934-1908
Links
Provider Directory
Visualizations
Co-author Network
Map of Science
Co-investigator Network
Racquel Innis-Shelton M.D.
Associate Professor
Positions
Associate Professor (P)
,
Medicine - Hematology & Oncology
,
Department of Medicine
Publications
Research
Background
Contact
Publications
Selected Publications
Academic Article
Filter
Year
Title
Altmetric
2022
Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer
.
Journal for ImmunoTherapy of Cancer
. 10.
2022
2021
Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation
.
American Journal of Hematology
. 96:E396-E398.
2021
2019
Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost Implications
.
Biology of Blood and Marrow Transplantation
. 25:233-238.
2019
2018
Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplant
.
Bone Marrow Transplantation
. 53:1345-1348.
2018
2018
Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma
.
Biology of Blood and Marrow Transplantation
. 24:1379-1385.
2018
2017
Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma
.
Biology of Blood and Marrow Transplantation
. 23:269-277.
2017
2017
Safety of repeated un-manipulated peripheral blood stem cell haploidentical transplant for graft failure
.
Bone Marrow Transplantation
. 52:157-158.
2017
2016
Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features
.
Cancer Causes and Control
. 27:81-91.
2016
2015
Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia
2015
2015
Telomere length in hematopoietic stem cell transplantation for severe aplastic anemia is it ready for "prime time"?
.
Journal of the American Medical Association
. 313:571-572.
2015
Chapter
Filter
Year
Title
Altmetric
2019
Sources of cells for hematopoietic cell transplantation
. 73-84.
2019
Research
Principal Investigator On
ASH Hematology Opportunities for the Next Generation of Research Scientist (Honors) Award
awarded by
American Society of Hematology ^
BMT CTN 1302- Multicenter Phase II, Double Blinded, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma
awarded by
National Marrow Donor Program
BMT CTN 1703/1801 A Randomized, Multicenter Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non Myeloablative / Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation and Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (Mi-Immune)
awarded by
National Marrow Donor Program
Private Grant
awarded by
GlaxoSmithKline
Prospective Observation of Cardiac Safety with Proteasome Inhibition (PROTECT)
awarded by
VANDERBILT UNIVERSITY
UAB 1355-A Randomized Phase III Study Comparing Conventional Dose Treatment using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009)
awarded by
Dana-Farber Cancer Institute
Investigator On
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML
awarded by
National Marrow Donor Program
Hematopoietic Stem Cell Therapy for Young Adults with Severe Sickle Cell Disease
awarded by
Emory University
IUAB 1677: Optimizing Post-Allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma using Ibrutinib
awarded by
VANDERBILT UNIVERSITY
International Myeloma Foundation Study of the Outcomes of Myeloma Patients with t(11;14) Translocation
awarded by
International Myeloma Foundation
Molecular Characterization of Myeloma and Related Asymptomatic Precursor States
awarded by
National Cancer Institute/NIH/DHHS
Multi-center, Single Arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for Non-Remission Acute Myeloblastic Leukemia (AML) using Clofarabine and Busulfan x 4 (CloBu4) Regimen
awarded by
University of Michigan
Private Grant
awarded by
AASTROM BIOSCIENCES, INC.
Private Grant
awarded by
ASTELLAS PHARMA US, INC.
Private Grant
awarded by
MILLENNIUM PHARMACEUTICALS, INC.
Private Grant
awarded by
ARRAY BIOPHARMA
Private Grant
awarded by
JANSSEN RESEARCH & DEVELOPMENT, LLC
Private Grant
awarded by
ONYX PHARMACEUTICALS, INC.
Private Grant
awarded by
KARYOPHARM THERAPEUTICS, INC.
Private Grant
awarded by
BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
Private Grant
awarded by
ABBVIE INC
Private Grant
awarded by
FATE THERAPEUTICS, INC.
Private Grant
awarded by
F.Hoffmann-La Roche Ltd.
Private Grant
awarded by
JANSSEN RESEARCH & DEVELOPMENT, LLC
Private Grant
awarded by
CELGENE CORPORATION
Private Grant
awarded by
AMGEN, INC.^
Private Grant
awarded by
Janssen
Private Grant
awarded by
CELGENE INTERNATIONAL II SÀRL
Private Grant
awarded by
GlaxoSmithKline
Private Grant
awarded by
JUNO THERAPEUTICS
Private Grant
awarded by
MUNDIPHARMA
Private Grant
awarded by
FATE THERAPEUTICS, INC.
Private Grant
awarded by
CELGENE CORPORATION
Private Grant
awarded by
CELGENE CORPORATION
Private Grant
awarded by
ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW
Private Grant
awarded by
BLUEBIRD BIO INC.
Private Grant
awarded by
MILLENNIUM PHARMACEUTICALS, INC.
Private Grant
awarded by
JANSSEN RESEARCH & DEVELOPMENT, LLC
Private Grant
awarded by
BLUEBIRD BIO INC.
Private Grant
awarded by
SYNDAX PHARMACEUTICALS, INC.
Private Grant
awarded by
CAREVIVE SYSTEMS, INC.
Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease, BMT CTN PROTOCOL #1507
awarded by
National Marrow Donor Program
The Role of Exosome Heparanase and miRNAs as Biomarkers for Myeloma
awarded by
National Cancer Institute/NIH/DHHS
UAB 1815: Phase 2 Trial of Intensive Chemo-immu,otherapy with Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed.Refractory Myeloma In the context of Salvage Autologous Hematopoietic Cell Transplantation
awarded by
Memorial Sloan-Kettering Cancer Center
Background
Education And Training
Atlanta Medical Center, Internship
Atlanta Medical Center, Residency
UAB Hospital, Postdoctoral Fellowship
University of Virginia Hospital, Postdoctoral Fellowship
Doctor of Medicine in Internal Medicine Residency Program,
Medical College of Georgia
1998
Contact
Full Name
Racquel
Innis-Shelton